Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

rations in this and future financial statements and therefore do not appear in the comparisons above regarding on-going operations.

As of December 31, 2012, InterMune had cash, cash equivalents and available-for-sale securities of approximately $308.0 million. The year-end 2012 cash balances do not include net proceeds from InterMune's concurrent offerings of common stock and convertible notes, which were completed in January 2013.

Guidance for 2013 Revenue and Operating Expenses
The company reiterated its forward-looking financial guidance for Esbriet revenue and operating expenses in 2013:

  • Esbriet revenue: currently projected to be in a range of$40 to $70 million.  This includes projected revenue in a range of $40 to $55 million in countries where Esbriet is currently launched (Germany, France, Canada and seven mid-sized European countries), and projected revenue in a range of $0 to $15 million in countries where Esbriet pricing and reimbursement approval and launch is not yet concluded but is currently anticipated during 2013 (Italy, UK, Spain and three mid-sized European countries).  The guidance also accounts for the three to six quarters needed from the date of conclusion of an agreement on pricing and reimbursement to comply with regional and provincial reimbursement procedures in Italy, Spain and Canada before meaningful Esbriet revenues can be achieved in all regions or provinces in these countries.
  • R&D expense: currently anticipated to be in a range of $100 to $120 million.
  • SG&A expense: currently anticipated to be in a range of $145 to $165 million. 
  • Total Operating Expenses (R&D and SG&A): currently anticipated to be in a range of $245 to $285 million.
  • Conference Call and Webcast Details
    InterMune will host a live webcast of a conference call today at 4:30 p.m. EST to discuss business highlights and financial results for the fourth quarter and full
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/31/2015)... Orlando, Florida (PRWEB) March 31, 2015 ... announced the official relocation of their U.S. facilities and ... more than 25 years of experience, Cryos’ relocation is ... presence. , The move to Orlando was completed during ... with an official opening taking place on April 6. ...
    (Date:3/30/2015)... March 30, 2015  Multiple new research abstracts suggest ... important health factors. From their impact on colon cancer ... effect on both gut health and vascular health, the ... our latest understanding of walnuts, inner workings. Running March ... , this annual meeting attracts an international audience of ...
    (Date:3/30/2015)... Md. , March 30, 2015 CASI ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a commercial focus on ... Food and Drug Administration (CFDA) has approved the Company,s ... in ovarian clear cell carcinoma (OCCC) patients for its ...
    (Date:3/30/2015)... England , March 30, 2015 ... developing novel biological drugs to treat cancer, viral ... of Professor Sir John Bell , the ... Chairman of the Office for the Strategic Coordination ... with immediate effect.      (Photo: ...
    Breaking Biology Technology:Cryos International Completes Groundbreaking Sperm Migration to Orlando, Florida 2New Findings Support the Benefits of Eating Walnuts on Overall Health 2New Findings Support the Benefits of Eating Walnuts on Overall Health 3New Findings Support the Benefits of Eating Walnuts on Overall Health 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5
    ... JERUSALEM , May 26, 2010 , ... - Study Data Shows ORMD-0801 Resulted in Glucose and ... Oramed Pharmaceuticals ... that the,paper entitled, "Open-label study to assess the safety and pharmacodynamics,of five oral insulin ...
    ... CHICAGO , May 26 Advanced Life ... a biopharmaceutical company engaged in the discovery, development and commercialization ... and respiratory diseases, today announced positive results from in ... efficacy of Restanza™ (cethromycin), its novel oral antibiotic, against the ...
    ... ... At the beginning of 2010, MIND360.com launched a ... played mind360’s brain training games as a creative and fun way ... and visual perception. The pilot was declared a success, showing an ...
    Cached Biology Technology:Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 2Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 2Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 5High School Brain Training - A Successful Pilot 2High School Brain Training - A Successful Pilot 3
    (Date:3/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces its biometric payment technology, the Wocket® ... television starting March 30 th . ... New York markets. ... about our new ad campaign following the recent initial shipment ...
    (Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
    (Date:3/18/2015)... As mobile payments become more prevalent ... and apps continue to be introduced into the market place ... payment industry in focus today are:  NXT-ID, Inc. (NASDAQ: ... BABA ), Apple Inc. (NASDAQ: AAPL ), Google ... FB ) NXT-ID, Inc. (NASDAQ: ...
    Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
    ... CHICAGO The Kappa Delta Sorority and the Orthopaedic ... to scientists who are helping to close the gap ... at the 2013 Annual Meeting of the American Academy ... recent discoveries in the following areas of musculoskeletal health: ...
    ... of the most southerly populations of polar bears in the world ... climate-induced changes to sea ice, new research reveals. Based on over ... Journal of Animal Ecology , sheds new light on how ... the ice. Lead by Dr Seth Cherry of the University ...
    ... House paint containing dangerous,concentrations of lead is being sold ... is refusing to remove the paint from store shelves. ... restrict the lead content of paint in,Cameroon to protect ... International (OK International) and co-author of a new,research study ...
    Cached Biology News:AAOS awards recognize innovative orthopaedic research 2AAOS awards recognize innovative orthopaedic research 3AAOS awards recognize innovative orthopaedic research 4For polar bears, it's survival of the fattest 2US company identified as manufacture of lead paint in Africa 2